Zymeworks Inc. ZYME 深 滬
等待開盤 03-26 09:30:00 美东时间
24.23
+0.630
+2.67%
華盛通- 最 高24.82
- 今 開23.96
- 成交量 52.22万股
- 最 低 23.96
- 昨 收 23.60
- 總市值 18.00亿
- 52周最高 28.49
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 9.03
- 委 比 -51.06%
- 總股本 7430.28万
- 歷史最高 59.03
- 量 比 0.90
- 振 幅 3.64%
- 歷史最低 4.11
- 每 手 1
- 風險率 5.36%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
BRIEF-Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics Alteogen Inc 196170.KQ : ALTEOGEN ENTERS INTO A LICENSE AGREEMENT WITH BIOGEN FOR DEVELOPMENT AND COMMERCIALIZATION OF HYBROZYME™-BASED SUBCUTANEOUS BIOLOGICS A
03-25 20:30
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Inc. (Nasdaq: ZYME) announced that its management will participate in two upcoming investor conferences. On April 15, they will present at the Needham 25th Annual Virtual Healthcare Conference at 10:15 am ET. On April 21, they will participate in the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto, ON. Zymeworks, a global biotechnology company, focuses on developing multifunctional biotherapeutics for various diseases,...
03-24 10:00
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
ZYME announced that new clinical and preclinical data for its ADC candidates ZW191, ZW437, and ZW418 will be presented at the AACR meeting in April 2026. ZW191, a folate receptor alpha-targeting ADC, shows strong anti-tumor activity when combined with standard-of-care agents. New candidates from the novel pan-RAS inhibitor ADC platform demonstrate potent activity across RAS-mutated cancers. The company also shared updates on its mRNA translation ...
03-17 21:02
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Evercore ISI Group Maintains Outperform on Zymeworks, Raises Price Target to $48
Evercore ISI Group analyst Jonathan Miller maintains Zymeworks (NASDAQ:ZYME) with a Outperform and raises the price target from $33 to $48.
03-10 00:20
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Mon...
03-09 20:05
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
Zymeworks Earnings Call: Zanidatumab Drives Bullish Outlook
Zymeworks (($ZYME)) has held its Q4 earnings call. Read on for the main highlig...
03-09 08:19
U.S. RESEARCH ROUNDUP-Burlington Stores, Costco Wholesale, Oracle
U.S. RESEARCH ROUNDUP-Burlington Stores, Costco Wholesale, Oracle March 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Burlington Stores, Costco Wholesale and Oracle, on Friday. HIGHLIGHTS * Burlington Stores Inc BURL
03-06 14:35
美股大行评级 | 绩后暴跌超22%，MongoDB遭14家大行集团下调目标价；挪威邮轮、阿莎娜、Quantum Computing等也遭大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持NRX Pharmaceuticals"买入"评级，目标价从40美元升至45美元；RBC Capital：维持NUVATION BIO"跑赢大市"评级，目标价从12美元升至13美元
03-04 10:22
